Publications by authors named "Ruxian Zhong"
Article Synopsis
- This study evaluates the safety and effectiveness of SGLT2 inhibitors for treating type 1 diabetes by reviewing randomized controlled trials (RCTs) through a thorough literature search up to September 2022.! -
- It included 16 RCTs with a total of 7,192 patients, showing that SGLT2 inhibitors significantly lower key diabetes indicators such as HbA1c and fasting plasma glucose, while also reducing body weight and insulin dosage.! -
- The findings suggest that SGLT2 inhibitors do not increase the risk of hypoglycemia, urinary tract infections, or diarrhea, indicating they might be a safe option for managing type 1 diabetes.
Background: There are no reliable molecular targets for early diagnosis and effective treatment in the clinical management of diabetic kidney disease (DKD). To identify novel gene factors underlying the progression of DKD.
Methods: The public transcriptomic datasets of the alloxan-induced DKD model and the streptozotocin-induced DKD model were retrieved to perform an integrative bioinformatic analysis of differentially expressed genes (DEGs) shared by two experimental animal models.
miR-223-3p mediates the diabetic kidney disease progression by targeting IL6ST/STAT3 pathway.
Biochem Biophys Res Commun
March 2023
Diabetic kidney disease (DKD), the most pervasive complication in diabetic patients, has become a major health threat to the aging population. Our previous miRNA profiling identified hsa-miR-223-3p as a dysregulated miRNA in the DKD samples, which may serve as a biomarker for DKD diagnosis. However, the specific mechanism of miR-223-3p in the pathogenesis of DKD remains to be elucidated.
View Article and Find Full Text PDF